Immunobiology and treatment of cutaneous T-cell lymphoma

被引：0

作者：

Goel, Rishi R. ^{[1
,2
]}

Rook, Alain H. ^{[1
]}

机构：

[1] Univ Penn, Perelman Sch Med, Dept Dermatol, Philadelphia, PA 19104 USA

[2] Univ Penn, Inst Immunol & Immune Hlth I3H, Perelman Sch Med, Philadelphia, PA USA

来源：

EXPERT REVIEW OF CLINICAL IMMUNOLOGY | 2024年 / 20卷 / 08期

关键词：

Cutaneous T cell lymphoma; CTCL; mycosis fungoides; Sezary syndrome; cutaneous oncology; immunotherapy; CHIMERIC ANTIGEN RECEPTOR; FIBROBLAST ACTIVATION PROTEIN; TUMOR BLOOD-VESSELS; ANTITUMOR-ACTIVITY; CHECKPOINT BLOCKADE; PHASE-I; ALPHA-V-BETA-3; INTEGRIN; STROMAL FIBROBLASTS; MONOCLONAL-ANTIBODY; ESTABLISHED TUMORS;

D O I：

10.1080/1744666X.2024.2326035

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

IntroductionPrimary cutaneous T cell lymphomas (CTCL) are a heterogenous group of non-Hodgkin lymphomas derived from skin-homing T cells. These include mycosis fungoides and its leukemic variant Sezary syndrome, as well as the CD30+ lymphoproliferative disorders.Areas CoveredIn this review, we provide a summary of the current literature on CTCL, with a focus on the immunopathogenesis and treatment of mycosis fungoides and Sezary syndrome.Expert OpinionRecent advances in immunology have provided new insights into the biology of malignant T cells. This in turn has led to the development of new therapies that modulate the immune system to facilitate tumor clearance or target specific aspects of tumor biology.

引用

页码：985 / 996

页数：12

共 126 条

[1] Retinoic acid receptor agonist as monotherapy for early-stage mycosis fungoides: does it work? [J].

Amitay-Laish, Iris ;

Reiter, Ofer ;

Prag-Naveh, Hadas ;

Kershenovich, Ruben ;

Hodak, Emmilia .

JOURNAL OF DERMATOLOGICAL TREATMENT, 2019, 30 (03) :258-263

[2] Autoimmunity associated with immunotherapy of cancer [J].

Amos, Sally M. ;

Duong, Connie P. M. ;

Westwood, Jennifer A. ;

Ritchie, David S. ;

Junghans, Richard P. ;

Darcy, Phillip K. ;

Kershaw, Michael H. .

BLOOD, 2011, 118 (03) :499-509

[3] Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies [J].

Ansell, Stephen M. ;

Maris, Michael B. ;

Lesokhin, Alexander M. ;

Chen, Robert W. ;

Flinn, Ian W. ;

Sawas, Ahmed ;

Minden, Mark D. ;

Villa, Diego ;

Percival, Mary-Elizabeth M. ;

Advani, Anjali S. ;

Foran, James M. ;

Horwitz, Steven M. ;

Mei, Matthew G. ;

Zain, Jasmine ;

Savage, Kerry J. ;

Querfeld, Christiane ;

Akilov, Oleg E. ;

Johnson, Lisa D. S. ;

Catalano, Tina ;

Petrova, Penka S. ;

Uger, Robert A. ;

Sievers, Eric L. ;

Milea, Anca ;

Roberge, Kathleen ;

Shou, Yaping ;

O'Connor, Owen A. .

CLINICAL CANCER RESEARCH, 2021, 27 (08) :2190-2199

[4] Enhanced expression of T-cell activation and natural killer cell antigens indicates systemic anti-tumor response in early primary cutaneous T-cell lymphoma [J].

Asadullah, K ;

Friedrich, M ;

Docke, WD ;

Jahn, S ;

Volk, HD ;

Sterry, W .

JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1997, 108 (05) :743-747

[5] Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion [J].

Assaf, C. ;

Bagot, M. ;

Dummer, R. ;

Duvic, M. ;

Gniadecki, R. ;

Knobler, R. ;

Ranki, A. ;

Schwandt, P. ;

Whittaker, S. .

BRITISH JOURNAL OF DERMATOLOGY, 2006, 155 (02) :261-266

[6] Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory / relapsed cutaneous T-cell lymphoma [J].

Aviles, Agustin ;

Neri, Natividad ;

Fernandez-Diez, Jorge ;

Silva, Luis ;

Nambo, Maria-Jesus .

HEMATOLOGY, 2015, 20 (09) :538-542

[7] INFECTIONS COMPLICATING MYCOSIS-FUNGOIDES AND SEZARY-SYNDROME [J].

AXELROD, PI ;

LORBER, B ;

VONDERHEID, EC .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 267 (10) :1354-1358

[8] IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial [J].

Bagot, Martine ;

Porcu, Pierluigi ;

Marie-Cardine, Anne ;

Battistella, Maxime ;

William, Basem M. ;

Vermeer, Maarten ;

Whittaker, Sean ;

Rotolo, Federico ;

Ram-Wolff, Caroline ;

Khodadoust, Michael S. ;

Bensussan, Armand ;

Paturel, Carine ;

Bonnafous, Cecile ;

Sicard, Helene ;

Azim, Hatem A., Jr. ;

Kim, Youn H. .

LANCET ONCOLOGY, 2019, 20 (08) :1160-1170

[9] KIR3DL2 expression in cutaneous T-cell lymphomas: expanding the spectrum for KIR3DL2 targeting [J].

Battistella, Maxime ;

Leboeuf, Christophe ;

Ram-Wolff, Caroline ;

Hurabielle, Charlotte ;

Bonnafous, Cecile ;

Sicard, Helene ;

Bensussan, Armand ;

Bagot, Martine ;

Janin, Anne .

BLOOD, 2017, 130 (26) :2900-2902

[10] Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression [J].

Bennani, N. Nora ;

Kim, Hyo Jin ;

Pederson, Levi D. ;

Atherton, Pamela J. ;

Micallef, Ivana N. ;

Thanarajasingam, Gita ;

Nowakowski, Grzegorz S. ;

Witzig, Thomas ;

Feldman, Andrew L. ;

Ansell, Stephen M. .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (06)

← 1 2 3 4 5 6 7 8 9 10 →